Arndt Rolfs | CEO - subrosa OmicAI
subrosa Health & Capital
Identifying Rare. Early. Globally. Proven outcome. Published. At subrosa OmicsAI, our mission is crystal clear: to find the invisible patients. Too many individuals with rare genetic disorders remain undiagnosed for far too long - living without answers, treatments, or hope. We have a new kind of platform: one that combines the power of omics technologies, real‑world data, and AI‑driven models to identify patients earlier, more accurately, and always ethically. Because behind every data point is a patient - and every diagnosis can change a life. I am humbled to walk this path with an incredibly passionate and visionary team. This is more than innovation - it’s a movement for visibility, dignity, and solutions. If you’re working in rare diseases, genomics, digital health, AI in healthcare, orphan drugs, or orphan diseases, I’d love to connect. Together, we can make the unseen seen! subrosa OmicsAI - a part of the subrosa Health & Capital Group. https://www.linkedin.com/in/prof-dr-arndt-rolfs/
Appearances:
Day 1 - World Orphan Drug Congress USA 2026 @ 12:30
Presentation: Beyond AI Predictions: Identifying Early Rare Disease Patients Through Real-Patient-Evidence Data
Many patient identification stategeies rely on AI-generated probabilities, digital signals or estimated cohorts. But a probability is not a real patient. This session introduces a fundamentally different approach.
SUBROSA OMICS AI's clinical patient identification programs are built on our proprietary global repositories of rare disease patients - genetically confirmed, sourced from real clinical diagnostics, not from algorithmic predictions. We demonstrate how our rare disease scientists from 29 offices across US, Europe, China, APAC, GIS, GCC and LATAM run the clinical studies aligned with your medical team. By recruiting new cohorts in a unique way, patients are detected years earlier than today's standards.
Hitting a precisely calculated success rate. Proven in more than 50 worldwide projects. Published. Indentification without access is only one slide in a deck. Holistic Patient access by SUBROSA OMICS AI accelerates outcomes. We keep both physicians & patients engaged across the full clinical journey through sustained communication. Ensuring that patients receive treatment & stay adherent - even in the markets without product authorizations via individual named patient programs.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events